{
    "data": [
        {
            "id": "69a09f4124c37e0001bb99d1",
            "title": "Something Unseen Since The Russian Invasion Of Ukraine Is Happening On Wall Street",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\">The first two months of 2026 have produced a sector divergence not seen on Wall Street since the <a href=\"https://www.benzinga.com/markets/tech/26/02/50869554/ai-winners-losers-us-sector-rotation-labor-exposure\" target=\"_blank\">shock of February 2022.</a></p><!--/$--><!--$--><p class=\"block core-block\">Back then, Russia's invasion of Ukraine triggered a violent rotation into energy and commodities.  </p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">Oil spiked. Defense stocks surged. Technology sold off on inflationary concerns.</p><!--/$--><!--$--><p class=\"block core-block\">Now it's happening again — but for a very different reason.</p><!--/$--><!--$--><p class=\"block core-block\">Through Feb. 26, 2026, the <strong>Energy Select Sector SPDR Fund</strong> <a class=\"ticker-link\" data-exchange=\"ARCA\" data-ticker=\"XLE\" href=\"https://www.benzinga.com/quote/XLE\" rel=\"noopener\" target=\"_blank\">(NYSE:</a><a class=\"ticker\" href=\"https://www.benzinga.com/quote/XLE\" target=\"_blank\">XLE</a>)<!-- --> has outperformed the <strong>Technology Select Sector SPDR Fund </strong><a class=\"ticker-link\" data-exchange=\"ARCA\" data-ticker=\"XLK\" href=\"https://www.benzinga.com/quote/XLK\" rel=\"noopener\" target=\"_blank\">(NYSE:</a><a class=\"ticker\" href=\"https://www.benzinga.com/quote/XLK\" target=\"_blank\">XLK</a>)<!-- --> by 27 percentage points.</p><!--/$--><!--$--><p class=\"block core-block\">That is the largest two-month performance gap between Energy and Technology since February 2022.</p><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--><!--$?--><template id=\"B:2\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\">Unlike four years ago, there has been no oil supply shock, no sudden war escalation and no surge in crude comparable to the post-invasion spike.</p><!--/$--><!--$--><p class=\"block core-block\">Instead, the growing gap between energy and tech reflects a new shift — one driven by AI. </p><!--/$--><!--$?--><template id=\"B:3\"></template><div></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">Wall Street Is Rotating — Not Retreating</h2><!--/$--><!--$--><p class=\"block core-block\">Crucially, investors are not abandoning equities.</p><!--/$--><!--$--><p class=\"block core-block\">They are reallocating within them.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">Energy, materials and industrial stocks have led gains since the start of the year. Technology, communication services and financial are lagging.</p><!--/$--><!--$--><p class=\"block core-block\">Equal-weight indices have recently outperformed capitalization-weighted benchmarks — often interpreted as a sign that returns are spreading beyond a handful of mega-cap technology names.</p><!--/$--><!--$?--><template id=\"B:4\"></template><div></div><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">Notably, the Invesco S&amp;P 500 Equal Weight ETF has outperformed the SPDR S&amp;P 500 ETF Trust for four consecutive months — the longest such stretch since January 2023. </p><!--/$--><!--$--><h2 class=\"wp-block-heading\">The AI paradox</h2><!--/$--><!--$--><p class=\"block core-block\">Artificial intelligence was supposed to lift the whole technology sector. Instead, it is redrawing the map.</p><!--/$--><!--$--><p class=\"block core-block\">AI increases productivity, but it can also squeeze margins in labour-intensive businesses. </p><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><p class=\"block core-block\">If software, coding or customer support can be automated at near-zero cost, investors inevitably question how durable those profits really are.</p><!--/$--><!--$--><p class=\"block core-block\">At the same time, the companies building AI are spending heavily on data centers, power supply and industrial equipment. </p><!--/$--><!--$--><p class=\"block core-block\">AI may be digital, but it runs on concrete, steel and electricity.</p><!--/$--><!--$--><h2 class=\"wp-block-heading\">The HALO Trade And The Map Of The New AI Winners</h2><!--/$--><!--$--><p class=\"block core-block\">A new analysis from Goldman Sachs suggests investors are beginning to price in which industries benefit from AI — and which are vulnerable to it.</p><!--/$--><!--$--><p class=\"block core-block\">The firm screened companies based on two factors: how exposed their labor force is to AI-driven automation, and how large labor costs are relative to revenue.</p><!--/$--><!--$--><p class=\"block core-block\">Sectors such as software, professional services and media rank high on both measures — meaning their margins could face structural pressure if AI reduces the scarcity of white-collar work.</p><!--/$--><!--$--><p class=\"block core-block\">By contrast, energy, utilities, materials and other asset-heavy industries carry lower labor intensity and higher tangible asset backing.</p><!--/$--><!--$--><p class=\"block core-block\">Goldman calls the emerging leadership theme HALO — Heavy Assets, Low Obsolescence.</p><!--/$--><!--$--><p class=\"block core-block\">In other words, the market may be shifting its premium from scalable code to hard-to-replicate infrastructure.</p><!--/$--><!--$--><p class=\"block core-block\">If that framework holds, the widening gap between energy and technology isn't just a trade.</p><!--/$--><!--$--><p class=\"block core-block\">It's the consequence of investors repricing what scarcity looks like in an AI-driven economy.</p><!--/$--><!--$--><p class=\"block core-block\"><em>Image created using artificial intelligence via Midjourney.</em></p><!--/$--><!--$--><div class=\"bz-optimizely-campaign bz-optimizely-campaign-bottom-50905025\" data-nosnippet=\"true\"></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2026/02/26/Wall-Street-ai6.png",
            "link": "https://www.benzinga.com/etfs/broad-u-s-equity-etfs/26/02/50905025/ai-driven-sector-rotation-wall-street-why-energy-outperforms-tech-2026-goldman-halo-trade",
            "pub_date": "2026-02-27 03:30:13",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a0a04824c37e0001bb9abc",
            "title": "Howard Marks: AI Is Multi-Trillion Dollar &#39;Labor Replacement,&#39; But Prediction Markets Disagree",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\"><strong>Howard Marks</strong> says AI has crossed from helping workers to replacing them.</p><!--/$--><!--$--><p class=\"block core-block\">The Oaktree Capital Management co-chairman released a memo Wednesday titled “AI Hurdles Ahead,” arguing that AI has hit what he calls “Level 3”, autonomous agents that do entire jobs, not just speed them up. </p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">That distinction, Marks writes, “is what separates a $50 billion market from a multi-trillion dollar one.”</p><!--/$--><!--$?--><template id=\"B:2\"></template><div></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">‘Not A Rough Draft. The Finished Thing.’</h2><!--/$--><!--$--><p class=\"block core-block\">Marks builds his case through a series of recent examples. </p><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--><!--$--><p class=\"block core-block\"><strong>Matt Schumer</strong>, CEO of <strong>Other Side AI</strong>, wrote in a blog post viewed over 50 million times that he tells AI what to build in plain English “and it just appears. Not a rough draft I need to fix. The finished thing.”</p><!--/$--><!--$--><p class=\"block core-block\">The development side is moving just as fast. </p><!--/$--><!--$--><p class=\"block core-block\"><strong>OpenAI’s</strong> technical documentation for GPT 5.3 Codex says it was the company’s “first model that was instrumental in creating itself.” </p><!--/$--><!--$--><p class=\"block core-block\"><strong>Anthropic</strong> CEO <strong>Dario Amodei</strong> says that feedback loop may be one to two years from full autonomy.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">Marks’ <a href=\"https://www.youtube.com/watch?v=b9BbEFQ0fUQ\" target=\"_blank\">memo</a> also cites an estimate that in software alone, $150 billion to $250 billion in annual labor value could migrate to AI compute.</p><!--/$--><!--$--><h2 class=\"wp-block-heading\">Prediction Markets Aren’t Panicking</h2><!--/$--><!--$--><p class=\"block core-block\">Polymarket’s How High Will US Unemployment Go In 2026? <a href=\"https://polymarket.com/event/how-high-will-us-unemployment-go-in-2026\" target=\"_blank\">market</a> gives a 38% chance unemployment hits 5.0% this year. Just 26% for 5.5%, 18% for 6.0% and 7% for 10.0%.</p><!--/$--><!--$--><p class=\"block core-block\">That 10% figure is the exact level <a href=\"https://www.benzinga.com/crypto/cryptocurrency/26/02/50784384/viral-2028-global-intelligence-crisis-models-potential-ai-driven-sp-500-crash-to-3500\" target=\"_blank\">Citrini’s dystopian scenario</a> modeled. Bettors are pricing it as a 20-to-1 long shot.</p><!--/$--><!--$--><p class=\"block core-block\">Apart from a spike during Covid, the U.S. hasn’t seen 10% unemployment since October 2009, at the depths of the financial crisis.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$?--><template id=\"B:3\"></template><div></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">What Investors Need To Know</h2><!--/$--><!--$--><p class=\"block core-block\">Marks isn’t calling it a bubble. </p><!--/$--><!--$--><p class=\"block core-block\">He says the technology is “very real” and its potential is “more likely underestimated today rather than overestimated.”</p><!--/$--><!--$--><p class=\"block core-block\">But he separates the tech from the trade. </p><!--/$--><!--$--><p class=\"block core-block\">Startups with multi-billion dollar valuations and no announced products, Marks writes, “can only be viewed as lottery tickets.”</p><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$?--><template id=\"B:4\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\">His advice from <a href=\"https://www.benzinga.com/markets/tech/25/12/49300024/howard-marks-weighs-in-on-ai-frenzy-dont-go-all-in-or-all-out-amid-debt-funded-winner-take-all-risks\" target=\"_blank\">December</a> hasn’t changed: don’t go all in and risk ruin, don’t stay all out and miss one of the great technological leaps forward.</p><!--/$--><!--$--><p class=\"block core-block\"><em>Image: Shutterstock</em></p><!--/$--><!--$--><div class=\"bz-optimizely-campaign bz-optimizely-campaign-bottom-50905209\" data-nosnippet=\"true\"></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2026/02/26/Robot-Hand-Chat-With-Ai--Artificial-Inte_1.jpeg",
            "link": "https://www.benzinga.com/markets/prediction-markets/26/02/50905209/howard-marks-ai-is-multi-trillion-dollar-labor-replacement-but-prediction-markets-disagree",
            "pub_date": "2026-02-27 03:34:35",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a09e5c24c37e0001bb990d",
            "title": "Bristol Myers Says New Breast Cancer Drug Shows Survival Benefit In Pretreated Patients",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\"><strong>Bristol Myers Squibb Co. </strong><a class=\"ticker-link\" data-exchange=\"NYSE\" data-ticker=\"BMY\" href=\"https://www.benzinga.com/quote/BMY\" rel=\"noopener\" target=\"_blank\">(NYSE:</a><a class=\"ticker\" href=\"https://www.benzinga.com/quote/BMY\" target=\"_blank\">BMY</a>)<!-- --> shares are down on Thursday as the company releases <a href=\"https://www.benzinga.com/pressreleases/26/02/b50881681/systimmune-and-bristol-myers-squibb-highlight-positive-phase-iii-interim-topline-results-for-izalo\" rel=\"noreferrer noopener\" target=\"_blank\">positive interim results</a> from a Phase 3 trial of izalontamab brengitecan (Iza-bren), in collaboration with <strong>SystImmune Inc.</strong></p><!--/$--><!--$--><p class=\"block core-block\">This news comes as the broader market experienced mixed performance, with the Nasdaq slightly down while other indices showed modest gains.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">Breast Cancer Trial Data</h2><!--/$--><!--$--><p class=\"block core-block\">SystImmune’s parent company, <strong>Sichuan Biokin Pharmaceutical Co., Ltd., </strong>reported that Iza-bren met its dual primary endpoints of progression-free survival and overall survival in the interim analysis of the trial.</p><!--/$--><!--$--><p class=\"block core-block\">The trial patients with unresectable locally advanced or metastatic triple-<a href=\"https://www.benzinga.com/general/health-care\" rel=\"noreferrer noopener\" target=\"_blank\">negative breast cancer</a> (TNBC) whose disease progressed following prior taxane therapy.</p><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--><!--$--><p class=\"block core-block\">The update marks the third Phase 3 study where Iza-bren has achieved its primary endpoints, underscoring its potential in treating advanced triple-negative breast cancer.</p><!--/$--><!--$--><p class=\"block core-block\">The trial results indicate a statistically significant improvement in patient outcomes compared to chemotherapy options, which could lead to new treatment avenues for patients facing limited options. </p><!--/$--><!--$--><p class=\"block core-block\">Additionally, the drug has received Breakthrough Therapy Designation from both the U.S. FDA and China’s National Medical Products Administration for multiple indications.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">The broader market experienced gains on the previous trading day, with the S&amp;P 500 closing up 0.06% and the Dow Jones rising 0.13%. </p><!--/$--><!--$--><p class=\"block core-block\">Bristol Myers Squibb’s rise aligns with the overall positive sentiment, although the Technology sector saw a slight decline of 0.02%, indicating mixed conditions across different sectors.</p><!--/$--><!--$--><h2 class=\"wp-block-heading\">Technical Analysis</h2><!--/$--><!--$--><p class=\"block core-block\">Currently, the stock is trading 4.1% below its 20-day simple moving average (SMA) and 9.8% below its 100-day SMA, indicating some short-term weakness.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">Over the past 12 months, shares have increased, and they are currently positioned closer to their 52-week highs than lows, suggesting a strong performance relative to its historical range.</p><!--/$--><!--$--><p class=\"block core-block\">The RSI is at 44.45, which is considered neutral territory, indicating that the stock is neither overbought nor oversold. Meanwhile, MACD is at 0.15, below its signal line at 0.22, indicating bearish pressure on the stock.</p><!--/$--><!--$--><p class=\"block core-block\">The combination of neutral RSI and bearish MACD suggests mixed momentum for the stock.</p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong>Key Resistance</strong>: $63.00</li>\n<li><strong>Key Support</strong>: $60.00</li>\n</ul><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><p class=\"block core-block\"><strong>Analyst Consensus &amp; Recent Actions:</strong> The stock carries a Hold Rating with an <a href=\"https://www.benzinga.com/quote/NYSE:BMY/analyst-ratings\" rel=\"noreferrer noopener\" target=\"_blank\">average price target</a> of $60.09. Recent analyst moves include:</p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong>RBC Capital</strong>: Initiated with Sector Perform (Target $60.00) (Feb. 25)</li>\n<li><strong>Piper Sandler</strong>: Overweight (Raises Target to $75.00) (Feb. 23)</li>\n<li><strong>Barclays</strong>: Initiated with Overweight (Target $75.00) (Feb. 20)</li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><strong>BMY Price Action:</strong> Bristol-Myers Squibb shares were down 0.56% at $60.95 at the time of publication on Thursday, <a href=\"https://www.benzinga.com/pro/\" rel=\"noreferrer noopener\" target=\"_blank\">according to Benzinga Pro data</a>.</p><!--/$--><!--$--><p class=\"block core-block\"><em>Photo via Shutterstock</em></p><!--/$--><!--$--><div class=\"bz-optimizely-campaign bz-optimizely-campaign-bottom-50904840\" data-nosnippet=\"true\"></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2026/02/26/Breast-cancer.jpeg",
            "link": "https://www.benzinga.com/markets/large-cap/26/02/50904840/bristol-myers-says-new-breast-cancer-drug-shows-survival-benefit-in-pretreated-patients",
            "pub_date": "2026-02-27 03:26:23",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a09cc524c37e0001bb97ed",
            "title": "COVID-19 Vaccine Maker Novavax Swings To Profit As Sales Climb",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\"><strong>Novavax Inc.</strong> <a class=\"ticker-link\" data-exchange=\"NASDAQ\" data-ticker=\"NVAX\" href=\"https://www.benzinga.com/quote/NVAX\" rel=\"noopener\" target=\"_blank\">(NASDAQ:</a><a class=\"ticker\" href=\"https://www.benzinga.com/quote/NVAX\" target=\"_blank\">NVAX</a>)<!-- --> shares are up on Thursday following the company’s announcement of its fourth-quarter and <a href=\"https://www.benzinga.com/pressreleases/26/02/n50884747/novavax-reports-fourth-quarter-and-full-year-2025-financial-results-and-operational-highlights\" rel=\"noreferrer noopener\" target=\"_blank\">full-year 2025 financial</a> results.</p><!--/$--><!--$--><h2 class=\"wp-block-heading\">Earnings</h2><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">Novavax reported <a href=\"https://www.benzinga.com/calendars/earnings\" rel=\"noreferrer noopener\" target=\"_blank\">fourth-quarter earnings</a> of 11 cents, a shift from a loss of 51 cents a year ago. evenue for the fourth quarter was $147 million, a 67% year-over-year increase.</p><!--/$--><!--$--><p class=\"block core-block\">Novavax on Thursday said it beat its 2025 cost-cutting targets across both GAAP and Non-GAAP R&amp;D and SG&amp;A spending and is tightening future expense goals.</p><!--/$--><!--$--><p class=\"block core-block\">The company now expects Non-GAAP R&amp;D and SG&amp;A expenses (net of R&amp;D reimbursements) of $325 million in 2026, $225 million in 2027, and $200 million or less in 2028 (newly introduced target).</p><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">Management Commentary</h2><!--/$--><!--$--><p class=\"block core-block\">“In 2025, we made significant progress on our corporate strategy, marked with the successful achievement of key milestones under our Sanofi agreement, progress towards potential new partnerships, in the form of multiple MTAs signed with other parties enabling experimentation with our Matrix-M adjuvant technology and the advancement of our own R&amp;D efforts,” said <strong>John Jacobs</strong>, President and CEO, Novavax.</p><!--/$--><!--$?--><template id=\"B:2\"></template><div></div><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">Guidance</h2><!--/$--><!--$--><p class=\"block core-block\">Novavax highlighted a revenue forecast for 2026, projecting adjusted total revenue between $230 million and $270 million compared to the <a href=\"https://www.benzinga.com/calendars/guidance\" rel=\"noreferrer noopener\" target=\"_blank\">consensus of $381.22 million</a>.</p><!--/$--><!--$--><p class=\"block core-block\">The company expects to achieve $35 million to $45 million in Nuvaxovid product sales and $40 million to $50 million in adjusted supply sales, reflecting ongoing collaborations with partners like the Serum Institute.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">Technical Analysis</h2><!--/$--><!--$--><p class=\"block core-block\">Currently, the stock is trading 8.4% above its 20-day simple moving average (SMA) and 9.2% above its 100-day SMA, indicating short-term strength. Over the past 12 months, shares have increased significantly and are currently positioned closer to their 52-week highs than lows, reflecting a strong upward trend.</p><!--/$--><!--$--><p class=\"block core-block\">The RSI is at 44.45, which is considered neutral territory, suggesting that the stock is neither overbought nor oversold. Meanwhile, MACD is not available, but the absence of significant crossovers indicates a stable trend without immediate bullish or bearish pressure.</p><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><p class=\"block core-block\">The combination of neutral RSI and the absence of a MACD signal suggests mixed momentum, indicating that traders should watch for potential breakout or reversal signals in the near term.</p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong>Key Resistance</strong>: $12.00</li>\n<li><strong>Key Support</strong>: $10.50</li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><strong>Analyst Consensus &amp; Recent Actions:</strong> The stock carries a Hold Rating with an <a href=\"https://www.benzinga.com/quote/NASDAQ:NVAX/analyst-ratings\" rel=\"noreferrer noopener\" target=\"_blank\">average price target</a> of $32.23. Recent analyst moves include:</p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong>BTIG</strong>: Buy (Maintains Target to $19.00) (Jan. 20)</li>\n<li><strong>JP Morgan</strong>: Underweight (Lowers Target to $6.00) (Nov. 18, 2025)</li>\n<li><strong>B. Riley Securities</strong>: Buy (Lowers Target to $16.00) (Nov. 10, 2025)</li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><strong>NVAX Price Action:</strong> Novavax shares were up 21.15% at $11.55 at the time of publication on Thursday, according to <a href=\"https://pro.benzinga.com/dashboard\" rel=\"noreferrer noopener\" target=\"_blank\">Benzinga Pro data</a>.</p><!--/$--><!--$--><p class=\"block core-block\"><em>Photo: Shutterstock</em></p><!--/$--><!--$--><div class=\"bz-optimizely-campaign bz-optimizely-campaign-bottom-50904546\" data-nosnippet=\"true\"></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2026/02/26/Novavax-Vaccine.jpeg",
            "link": "https://www.benzinga.com/markets/earnings/26/02/50904546/covid-19-vaccine-maker-novavax-swings-to-profit-as-sales-climb",
            "pub_date": "2026-02-27 03:19:37",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a09d3024c37e0001bb9837",
            "title": "Stock Of The Day: False Breakout In Nvidia?",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$?--><template id=\"B:2\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\">It may be staging a classic false breakout.  This would suggest a continued move lower. It's why Nvidia is the <strong>Stock of the Day.</strong></p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\"><strong>     •  What’s weighing on<a href=\"https://www.benzinga.com/quote/NVDA\" rel=\"noreferrer noopener\" target=\"_blank\"> NVDA shares?</a></strong></p><!--/$--><!--$--><p class=\"block core-block\">It is unfortunate that technical analysis has a dubious reputation on Wall Street. But it isn't surprising.</p><!--/$--><!--$--><p class=\"block core-block\">Most technical analysts don't understand market dynamics and price action. They look for patterns on charts without understanding why these patterns form and what they mean. </p><!--/$--><!--$--><p class=\"block core-block\">This is why so many technical analysts are unsuccessful.</p><!--/$--><!--$--><p class=\"block core-block\">Chart patterns are graphical illustrations of the supply and demand dynamics playing out in a market. A classic ascending triangle pattern formed on the chart of Nvidia. These are considered bullish patterns.</p><!--/$--><!--$?--><template id=\"B:3\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\">As you can see on the chart, there was resistance around the $193.40 level going back to December. The line is horizontal because the sellers were patient. They were okay with staying at their prices and waiting for the buyers to come to them.</p><!--/$--><!--$--><p class=\"block core-block\">But over the same time period, traders and investors who wanted to buy became anxious and impatient. They were willing to pay successively higher prices. This is why the support line of the pattern is ascending.</p><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--><!--$--><p class=\"block core-block\">The ascending triangle is bullish because it is a graphical illustration of a market with patient and complacent sellers, and aggressive and impatient buyers. Regardless of the market, these dynamics can set the stage for a move higher.</p><!--/$--><!--$--><p class=\"block core-block\">But successful traders know that popular stocks such as Nvidia can act very differently than analysts and pundits anticipate. Just because a stock gets above resistance, it doesn't mean it will stay there.</p><!--/$--><!--$--><p class=\"block core-block\">It could end up being a false breakout. It looks like there is going to be a breakout, but then the stock reverses quickly and heads lower. As you can see on the chart, that may be the case today with Nvidia.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">Successful traders understand the dynamics that form patterns on charts. But they also understand that there are no rules in markets, only guidelines. The ability to remain flexible is one of the main reasons for their success.</p><!--/$--><!--$--><p class=\"block core-block\"><em>Photo: Michael Vi  via Shutterstock</em></p><!--/$--><!--$--><div class=\"bz-optimizely-campaign bz-optimizely-campaign-bottom-50904633\" data-nosnippet=\"true\"></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2026/02/26/Nvidia-Corporation.jpeg",
            "link": "https://www.benzinga.com/trading-ideas/technicals/26/02/50904633/stock-of-the-day-false-breakout-in-nvidia",
            "pub_date": "2026-02-27 03:21:23",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        }
    ]
}